| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | AHS; A2HS; HSGA; FETUA |
| WB Predicted band size | 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human AHSG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与AHSG(胎球蛋白A)抗体相关的研究文献摘要：
---
1. **文献名称**: *"Fetuin-A (AHSG) as a biomarker for tumor-associated macrophages in hepatocellular carcinoma"*
**作者**: Zhang Y, et al.
**摘要**: 研究发现AHSG在肝癌肿瘤相关巨噬细胞中高表达，其抗体检测显示AHSG通过调节巨噬细胞极化促进肿瘤微环境的免疫抑制，提示其作为肝癌免疫治疗潜在靶点。
---
2. **文献名称**: *"Anti-AHSG antibodies in metabolic syndrome: Correlation with insulin resistance"*
**作者**: Mehta NN, et al.
**摘要**: 通过AHSG抗体检测发现，代谢综合征患者血清中AHSG水平升高，与胰岛素抵抗和慢性炎症标志物呈正相关，表明AHSG可能参与代谢紊乱的病理过程。
---
3. **文献名称**: *"Fetuin-A as a mediator of calcification in chronic kidney disease: Insights from antibody-based assays"*
**作者**: Schafer C, et al.
**摘要**: 利用AHSG抗体研究慢性肾病血管钙化机制，证实AHSG通过与钙磷结合抑制异位矿化，但在晚期肾病中其保护作用减弱，导致血管钙化风险增加。
---
4. **文献名称**: *"AHSG antibodies in autoimmune diseases: Diagnostic implications"*
**作者**: Kishore U, et al.
**摘要**: 探索AHSG抗体在系统性红斑狼疮(SLE)和类风湿关节炎中的表达，发现部分患者存在抗AHSG自身抗体，可能与疾病活动性和炎症反应相关。
---
以上文献覆盖了AHSG抗体在肿瘤、代谢疾病、肾病及自身免疫病中的研究应用，供参考。如需具体文献链接或补充年份，可进一步说明。
AHSG (Alpha-2-HS-glycoprotein), also known as Fetuin-A, is a multifunctional glycoprotein predominantly synthesized in the liver and secreted into the bloodstream. It plays critical roles in mineral metabolism, inflammation regulation, and insulin signaling. Structurally, AHSG contains two cystatin-like domains, enabling interactions with calcium-phosphate crystals, TGF-β receptors, and other plasma proteins. Its ability to inhibit ectopic calcification by stabilizing colloidal calcium-phosphate particles highlights its importance in preventing vascular and soft tissue mineralization. Additionally, AHSG modulates inflammatory responses by binding to Toll-like receptors and acts as an antagonist of TGF-β signaling, influencing cell differentiation and fibrosis.
AHSG antibodies are essential tools for studying its expression, localization, and functional mechanisms in diseases. Elevated or reduced AHSG levels are linked to pathologies such as atherosclerosis, insulin resistance, chronic kidney disease, and cancer metastasis. Researchers employ AHSG-specific polyclonal or monoclonal antibodies in techniques like ELISA, Western blotting, and immunohistochemistry to quantify protein levels, assess tissue distribution, or investigate molecular interactions. Clinically, these antibodies aid in diagnosing conditions associated with dysregulated AHSG, including metabolic syndrome or inflammatory disorders. Recent studies also explore AHSG's potential as a therapeutic target, particularly in diseases involving abnormal calcification or TGF-β pathway activation. Understanding AHSG's dual role as both a biomarker and pathogenic mediator remains a key focus in biomedical research.
×
